Will TRI's GenAI-enabled ACV exceed 35% of total ACV by Q4 2026?

GenAI-enabled ACV grew from 15% to 28% over 5 quarters (~2.6pp/quarter average). Reaching 35% by Q4 2026 requires ~7pp additional over 4 quarters (~1.75pp/quarter) — a deceleration from recent pace would still suffice. However, the metric is a product-feature measure, not pure AI revenue. As the denominator grows and AI features become standard across products, the percentage naturally increases. The Myth Meter's DIVERGING classification suggests this metric may be inflating faster than underlying AI monetization.

The trajectory strongly favors YES. The growth from 15% to 28% reflects both new AI products (CoCounsel, Westlaw Advantage) and AI features being added to existing products. With Westlaw Advantage just launched and Ready to Review/Ready to Advise entering the market, the pipeline of AI-enabled product launches continues to grow. Management's explicit AI strategy and $200M+ annual investment commitment provide organizational tailwind. The 35% threshold is below the trajectory extrapolation (~38-39% if current pace holds).

While the mathematical trajectory favors YES, the Myth Meter's insight about this being a product-feature metric rather than a revenue metric introduces nuance. Companies often redefine what counts as 'AI-enabled' as the narrative evolves. TRI could easily reach 35% by broadening the definition of GenAI-enabled features across existing products. The real question is whether this metric maintains analytical value at 35% — it may become too diluted to signal genuine AI monetization progress. Still, the question asks only about the metric threshold, not its quality.

The math is straightforward: 28% current, 35% target, 4 quarters to go. That requires 1.75pp/quarter — well below the ~2.6pp/quarter average achieved over the last 5 quarters. Management has a massive AI investment commitment ($200M+/year) and institutional incentive to grow this metric. New product launches (Westlaw Advantage, Ready to Review/Advise) will add to the numerator. The most likely failure mode is a redefinition of the metric that makes it incomparable, not an actual failure to reach 35%.

Strong trajectory and management incentives favor YES. The 28% to 35% requires below-current-pace growth. However, S-curves do flatten — the early gains may have captured the easiest products to AI-enable, and the remaining portfolio may have slower AI adoption rates. Tax and Corporates segments may have more complex integration requirements. Also, if management discontinues or redefines this metric in 2026 (which companies do when metrics become less flattering), the question becomes unresolvable. Taking that risk into account modestly.

Management has every incentive and capability to hit this number. The AI transformation narrative drives their premium multiple, and GenAI-enabled ACV is one of the few quantified AI metrics they provide. Dropping this metric or seeing it stall would be shareholder-unfriendly. The product pipeline (Westlaw Advantage, CoCounsel expansion, tax AI products) provides genuine catalysts. The 35% bar is modest relative to the trajectory.

Clear trajectory: 15% to 28% in 5 quarters = 2.6pp/quarter. Need 7pp more in 4 quarters = 1.75pp/quarter. Below recent pace. Multiple new AI products launching. Management strongly incentivized. High probability of YES.

Trajectory favors YES but some deceleration risk exists. Early AI-enabling of products captures low-hanging fruit. Complex products (tax calculation engines, compliance tools) may take longer to AI-enable meaningfully. Still, the required pace is well below current trajectory, making failure unlikely unless there is a significant strategic pivot.

Strong trajectory, management commitment, and new product pipeline all point to YES. The main risk is S-curve flattening or metric redefinition. At 28% currently with 4 quarters to go, reaching 35% requires only modest continuation of established trend. Probability well above 50%.